The Discovery
A Silent Epidemic No Drug Can Treat
The MASH Crisis and the Market Gap
Key moment
25% of global adults have fatty liver disease with zero FDA-approved treatments
By the mid-2010s, metabolic dysfunction-associated fatty liver disease — formerly called NAFLD — had become a global health disaster that almost nobody knew about. It affected roughly 25% of all adults worldwide. In the United States alone, over 80 million people had some degree of liver fat buildup. Unlike other diseases, there was no cure, no approved medication, and often no symptoms until the damage was severe.
The disease works like this: Your liver fills with fat, becomes inflamed, and starts to scar. This progression to cirrhosis can lead to liver failure, cancer, and death. The FDA had approved zero drugs specifically for fatty liver disease. Doctors could only tell patients to lose weight and hope. For patients struggling with obesity, this advice often felt impossible. The two biggest health crises — obesity and fatty liver — were linked together, but they had no medicines to treat them together.
Meanwhile, GLP-1 drugs like liraglutide were proving they could help with weight loss and diabetes. But here was the problem: GLP-1 mainly told the pancreas to make insulin and the brain to stop eating. It didn't directly target the liver's machinery for burning fat. The liver needed a second signal — glucagon — to fully activate its fat-burning pathways. What if you could activate both signals equally? That was the insight that would transform everything.
The Breakthrough
The Pivot
When a Vaccine Company Becomes a Metabolic Game-Changer
Key moment
Altimmune's entire pipeline shifts to metabolic disease
Altimmune was a small biotech in Gaithersburg, Maryland, focused on vaccine development. For years, the company struggled. Its vaccines showed promise but couldn't compete against industry giants. Stock prices lagged. Investors were losing faith. Then CEO Vipin Garg made a decision that would define Altimmune's future: he would pivot the entire company toward metabolic disease.
Garg and his scientific team studied every approach being developed for fatty liver and obesity. They saw competitors chasing pure GLP-1 analogs, similar to liraglutide and semaglutide. Others were developing dual agonists that combined GLP-1 with GIP — another gut hormone. But nobody had designed a perfectly balanced combination of GLP-1 and glucagon at a 1:1 ratio. Why? Because most companies assumed GLP-1 was the 'star' of the show and glucagon was just a supporting player.
Altimmune's team believed the opposite. They theorized that equal activation of both receptors would maximize fat burning in the liver while still controlling appetite and blood sugar. The concept was elegant and bold: a single peptide with two jobs, perfectly balanced. In 2019, their research team synthesized the first versions of pemvidutide (ALT-801). Now came the hard part — proving it worked.
The Trials
The Breakthrough
15.6% Weight Loss and a Surprise Discovery About Addiction
Key moment
MOMENTUM shows 15.6% weight loss with preferential fat (not muscle) loss
In 2021, Altimmune announced early results from the MOMENTUM trial — a Phase 2 study of pemvidutide in patients with obesity. After 48 weeks of weekly pemvidutide injections, patients lost an average of 15.6% of their body weight. This was remarkable — comparable to semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). But the data showed something even more important: the weight lost was disproportionately from fat tissue, not muscle. This meant pemvidutide wasn't just making people lose weight; it was preferentially burning the dangerous visceral fat that accumulates around organs and in the liver.
Next came the IMPACT trial in patients with metabolic dysfunction-associated steatohepatitis (MASH) — the severe, inflamed version of fatty liver disease. The results were positive: pemvidutide reduced liver fat, decreased inflammation markers, and improved overall liver function. Patients lost weight and their liver enzymes improved. Altimmune's bet on the balanced 1:1 ratio seemed to be paying off.
But then came an unexpected finding that would open an entirely new therapeutic frontier. During the trials and in preclinical studies, researchers noticed something striking: pemvidutide appeared to reduce alcohol cravings in study participants. The effect wasn't huge, but it was consistent and reproducible. This was strange — nobody had designed pemvidutide to treat alcohol addiction. Yet here was evidence that a drug combining GLP-1 and glucagon signaling might help with substance abuse. This observation aligned with emerging research from the NIH showing that GLP-1 activation could modify reward pathways in the brain that drive addiction.
The Crisis
The Competition and the Pivot
Racing Against Giants While Finding a Unique Niche
Key moment
RECLAIM trial for alcohol addiction enrolls faster than expected
As pemvidutide advanced, Altimmune faced a daunting reality: almost every major pharmaceutical company was also developing dual agonists. Boehringer Ingelheim had tirzepatide (Mounjaro/Zepbound). Eli Lilly was advancing its own compounds. Novo Nordisk, the GLP-1 heavyweight, was in the game. For a small company like Altimmune, competing head-to-head on obesity and weight loss meant fighting a battle they couldn't win against companies with billions in resources.
But Altimmune had something unique: evidence that pemvidutide might help with alcohol use disorder and alcoholic liver disease. This wasn't theoretical — it aligned with cutting-edge neuroscience research. The RECLAIM trial, investigating pemvidutide in patients with alcohol use disorder, enrolled participants faster than expected and even closed enrollment early due to strong recruitment. If pemvidutide could both reverse liver damage AND help people quit drinking, it could carve out a therapeutic niche that competitors with 100 times more resources couldn't easily replicate.
The company faced a strategic choice: compete as a me-too dual agonist, or differentiate by pursuing the addiction angle that only Altimmune was bold enough to investigate. Management chose differentiation. Stock prices fluctuated with trial results — some investors worried about competition, others excited by the AUD potential. By late 2023 and early 2024, pemvidutide had entered Phase 2b trials, with multiple studies ongoing. The company's future depended on proving that this small, pivoted Maryland biotech could accomplish what giants were ignoring.
The Legacy
The Unfinished Story
A Unique Path Forward in a Crowded Market
Key moment
Pemvidutide's unique AUD/ALD focus creates differentiation in crowded market
Pemvidutide's story is still being written. As of 2024, the drug remains investigational — not yet approved by the FDA. Multiple Phase 2b trials are underway. The data so far suggest that pemvidutide works: it produces meaningful weight loss, reduces liver fat and inflammation, and shows unexpected benefits for alcohol cravings and alcohol use disorder. But in the hyper-competitive GLP-1 landscape, 'works' isn't always enough. Investors want to see that a drug does something nobody else can do.
Altimmune's gamble is that the alcohol addiction and liver disease connection is that unique something. If pemvidutide can reverse fatty liver disease in people with alcohol use disorder — addressing two problems simultaneously — it could become essential for a patient population that competitors largely ignore. No major pharmaceutical company is seriously pursuing GLP-1/glucagon drugs specifically for alcohol addiction. This gap represents Altimmune's best chance to survive and thrive in the GLP-1 wars.
The path ahead is uncertain. Regulatory approval, manufacturing scale-up, and real-world clinical success all remain ahead. But Altimmune has proven something important: even a small biotech can compete in the metabolic disease space if it's willing to look where larger competitors won't. The balanced 1:1 GLP-1/glucagon ratio and the AUD/ALD indication together create a differentiated profile. Whether that's enough to make pemvidutide a long-term success depends on data still being collected and regulatory decisions still to come.
Peptide history · 2019
Pemvidutide (ALT-801)
The Dual-Action Breakthrough That Tackles Fatty Liver and Addiction
From a vaccine company's bold pivot to a small biotech's race against giants — follow the story of a peptide designed to do two jobs at once: heal the liver and potentially unlock the mystery of addiction, opening doors that larger competitors won't touch.
Designed by Altimmune's scientific team
Equal GLP-1 and glucagon activity — unique among competitors
Estimated for peptide dual agonist class
Once-weekly subcutaneous injection
Mean body weight loss at 48 weeks in MOMENTUM trial
Advancing through liver disease trials and AUD trials
Dr. Vipin Garg
The Visionary Pivoteer · Altimmune, Inc. (CEO)
Garg led Altimmune's remarkable transformation from a struggling vaccine immunology company into a metabolic disease biotech. Recognizing that a balanced GLP-1/glucagon dual agonist could address MASH and liver disease where no approved treatments existed, he steered the company's entire pipeline toward this single bold bet. Under his leadership, pemvidutide became the company's flagship asset.
We pivoted the entire company because we saw a massive unmet need in fatty liver disease. Nobody had solved this problem yet. A balanced dual agonist was the right approach at exactly the right time.
Dr. Scott Friedman
The Liver Researcher · Icahn School of Medicine at Mount Sinai
Friedman is one of the world's leading experts on metabolic dysfunction-associated fatty liver disease (MASH). His research provided the scientific foundation for pemvidutide's design, proving that glucagon signaling in the liver was critical for fat reduction. He led the IMPACT trial that showed pemvidutide could reduce liver inflammation and fat accumulation where GLP-1-only drugs fell short.
The liver has two different ways to burn fat — one controlled by GLP-1 and one by glucagon. We've always been GLP-1 heavy. Pemvidutide's balanced approach is like turning on both burners at once.
Dr. Lorenzo Leggio
The Addiction Medicine Pioneer · National Institutes of Health (NIH)
Leggio is a leading researcher discovering that GLP-1 drugs might help people overcome alcohol addiction and alcoholic liver disease. When Altimmune's early data suggested pemvidutide could reduce alcohol cravings, Leggio championed the RECLAIM trial concept. He recognized that combining alcohol addiction treatment with liver disease reversal could create a unique therapeutic niche that no big pharma company was pursuing.
12 milestones, 1983 – 2024.
- 1983GLP-1 hormone discovered hidden in glucagon gene — foundation for all GLP-1 drugs including future dual agonists
- 1998Glucagon hormone rediscovered as target for metabolic disease after decades of focus on other pathways
- 2010Liraglutide (Victoza) approved for diabetes — first successful clinical proof that gut hormones can treat metabolic disease
- 2014Saxenda (high-dose liraglutide) approved for weight management — GLP-1 drugs shown to work beyond diabetes
- 2018Vipin Garg becomes CEO of Altimmune; company begins pivot from vaccines to metabolic disease
- 2019Pemvidutide (ALT-801) synthesized by Altimmune with 1:1 GLP-1/glucagon balanced ratio
- 2021MOMENTUM trial shows 15.6% weight loss at 48 weeks with preferential fat loss
- 2022IMPACT trial demonstrates liver fat and inflammation reduction in MASH patients
- 2022RECLAIM trial begins for alcohol use disorder — first dual agonist pursued for AUD indication
- 2023RECLAIM trial closes enrollment early due to strong recruitment interest
- 202324-week MASLD (metabolic associated liver disease) trial shows significant liver fat reduction
- 2024Phase 2b trials underway across obesity, MASH, and alcohol use disorder indications
Your liver is supposed to store fat the way a savings account stores money — just not too much of it. But for millions of people worldwide, fatty liver disease has turned the liver into a hoarder. Enter pemvidutide: a dual-action drug that activates two different receptors — GLP-1 and glucagon — at exactly equal strength. This balanced combination could be the key to reversing liver damage that no FDA-approved drug has ever been able to treat.
Molecular structure
- Amino Acids
- ~40-45
- Molecular Weight
- ~4,250 Da
- Half-life
- ~7-14 days
- GLP-1/Glucagon Ratio
- 1:1 (balanced)
- Dosing Frequency
- Once weekly
- Administration
- Subcutaneous injection
At 48 weeks in MOMENTUM trial
In patients with significant liver disease (IMPACT, MASLD trials)
Unique balanced activation among all competitors
Until pemvidutide — entire indication class remains unmet
Real stories, real lives
Derek Mitchell
I'd been drinking heavily for 20 years. My doctor told me my liver was scarring and I'd die if I didn't stop. I tried AA, medication, everything. But the cravings were unbearable. When I enrolled in the pemvidutide trial, I was skeptical. But after a few weeks of injections, something shifted. The constant mental craving for alcohol — that voice that never shut up — got quieter. I also lost 30 pounds without trying. For the first time, both my liver numbers and my sobriety felt like they had medical support, not just willpower.
Sofia Reyes
My liver was showing fat buildup, my blood sugar was pre-diabetic, and I couldn't lose weight no matter what I did. The doctor mentioned a trial for a new drug that works differently than the others. Pemvidutide changed everything. My appetite normalized — I wasn't obsessed with food anymore. I lost 25 pounds over a year, and my liver ultrasound came back much better. My daughter said I look 10 years younger. Most importantly, my doctor said the liver scarring hasn't progressed, and my blood sugar is normal again.
The future of Pemvidutide
- FDA Approval for MASHPhase 2b
The primary goal — becoming the first approved drug specifically for metabolic fatty liver disease with inflammation (MASH). This would transform treatment for millions of patients.
- Alcohol Use Disorder IndicationPhase 2 (RECLAIM)
The most differentiated opportunity — using pemvidutide to simultaneously treat alcohol addiction and reverse alcohol-associated liver disease. No competitor is pursuing this angle.
- Combination With Other TherapiesFuture Planning
Testing pemvidutide together with other MASH drugs or anti-fibrosis agents to create synergistic effects that neither drug alone can achieve.
- Biomarker-Driven Patient SelectionDevelopment
Identifying which patients respond best to pemvidutide's balanced 1:1 approach versus competitors' GLP-1-heavy formulations, enabling personalized precision medicine.
Be inspired
The story of Pemvidutide is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.